R L Goodall
Overview
Explore the profile of R L Goodall including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
195
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goodall R, Fabiane S, Hakiman A, Crook A, Mirzayev F, Schumacher S, et al.
IJTLD Open
. 2024 Jul;
1(4):151-153.
PMID: 38988407
No abstract available.
2.
Hughes G, Bern H, Chiang C, Goodall R, Nunn A, Rusen I, et al.
Int J Tuberc Lung Dis
. 2022 Oct;
26(11):1065-1070.
PMID: 36281045
STREAM (Standardised Treatment Regimen of Anti-tuberculosis Drugs for Patients with Multidrug-resistant Tuberculosis) Stage 1 was a randomised trial of a Short (9-month) regimen for rifampicin-resistant TB (RR-TB). QT or QTcF...
3.
Kokebu D, Ahmed S, Moodliar R, Chiang C, Torrea G, Van Deun A, et al.
Int J Tuberc Lung Dis
. 2022 Jul;
26(8):753-759.
PMID: 35898125
STREAM (Standardised Treatment Regimens of Anti-tuberculosis drugs for Multidrug-Resistant Tuberculosis) Stage 1 demonstrated non-inferior efficacy of a short regimen for rifampicin-resistant TB (RR-TB) compared to a long regimen as recommended...
4.
Hughes G, Bern H, Chiang C, Goodall R, Nunn A, Rusen I, et al.
Int J Tuberc Lung Dis
. 2022 Mar;
26(4):334-340.
PMID: 35351238
STREAM (Standardized Treatment Regimen of Anti-TB Drugs for Patients with MDR-TB) Stage 1 demonstrated non-inferior efficacy of a shortened regimen (the Short regimen) for rifampicin-resistant TB (RR-TB) compared to the...
5.
Asad H, Collins I, Goodall R, Crichton S, Hill T, Doerholt K, et al.
HIV Med
. 2021 May;
22(8):631-640.
PMID: 33939876
Objectives: To investigate risk of AIDS and mortality after transition from paediatric to adult care in a UK cohort of young people with perinatally acquired HIV. Methods: Records of people...
6.
Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trial
Phillips P, Van Deun A, Ahmed S, Goodall R, Meredith S, Conradie F, et al.
BMC Med
. 2020 Nov;
18(1):314.
PMID: 33143704
Background: The STREAM trial demonstrated that a 9-11-month "short" regimen had non-inferior efficacy and comparable safety to a 20+ month "long" regimen for the treatment of rifampicin-resistant tuberculosis. Imbalance in...
7.
Goodall R, Dunn D, Pattery T, van Cauwenberge A, Nkurunziza P, Awio P, et al.
J Antimicrob Chemother
. 2014 Mar;
69(7):1938-44.
PMID: 24633208
Objectives: We investigated phenotypic and genotypic resistance after 2 years of first-line therapy with two HIV treatment regimens in the absence of virological monitoring. Methods: NORA [Nevirapine OR Abacavir study,...
8.
Dunn D, Goodall R, Munderi P, Kityo C, Ranopa M, Bacheler L, et al.
Antimicrob Agents Chemother
. 2011 Jul;
55(10):4575-80.
PMID: 21768516
Virological residual activity (VRA) denotes the degree of HIV RNA suppression achieved by antiretroviral therapy in the presence of resistant virus. This concept is particularly important in resource-limited settings, where...
9.
Feeney E, Chazallon C, OBrien N, Meiffredy V, Goodall R, Aboulker J, et al.
HIV Med
. 2011 May;
12(10):602-9.
PMID: 21599820
Objective: The aim of the study was to evaluate the predictive value of clinical and molecular risk factors, including peripheral blood mononuclear cell (PBMC) mitochondrial DNA (mtDNA) and mitochondrial RNA...
10.
Burton C, Goodall R, Samri A, Autran B, Kelleher A, Poli G, et al.
Clin Exp Immunol
. 2008 Apr;
152(2):252-7.
PMID: 18410636
INITIO is an open-labelled randomized trial evaluating first-line therapeutic strategies for human immunodeficiency virus-1 (HIV-1) infection. In an immunology substudy a tetanus toxoid booster (TTB) immunization was planned for 24...